Liraglutide and Weight Loss Among Suboptimal Metabolic Bariatric Surgery Responders​Liraglutide and Weight Loss Among Suboptimal Metabolic Bariatric Surgery Responders 

This randomized clinical trial examines the effect of liraglutide on weight loss, health outcomes, and adverse effects in people who had achieved a stable, suboptimal weight loss after adjustable gastric band surgery or who had regained more than 5% of their total body weight. ​This randomized clinical trial examines the effect of liraglutide on weight Read More

Dual GIP/GLP-1 Drug Linked to Fewer Deaths in Real-World Liver Disease Study​Dual GIP/GLP-1 Drug Linked to Fewer Deaths in Real-World Liver Disease Study 

(MedPage Today) — PHOENIX — Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, and major cardiovascular events compared with semaglutide (Ozempic, Wegovy) in high-risk patients with… ​ (MedPage Today) — PHOENIX — Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, and major cardiovascular Read More

Discovery of breast cancer treatment resistance mechanism could lead to new hope for some​Discovery of breast cancer treatment resistance mechanism could lead to new hope for some 

Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class of therapeutics called antibody drug conjugates (ADCs). These treatments pair an antibody that targets cancer cells with a strong chemotherapy drug. For many patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancers, ADCs such as trastuzumab deruxtecan (T-DXd) have dramatically improved outcomes.